Back to search

Article

EZH2-driven immune evasion at disease presentation defines a targetable high-risk subset of acute leukemia exemplified by t(16;21) FUS::ERG AML

2024-05-17

Abstract excerpt

<h4>ABSTRACT</h4> The past 25 years of clinical trials have produced few improvements in pediatric AML (pAML) outcomes. This is acutely evident in patients with t(16;21)(p11;q22), yielding FUS::ERG . Patients with FUS::ERG -positive AML relapse quickly and do not respond to transplantation. Major histocompatibility complex (MHC) class I & II receptors and costimulatory molecules are absent at diagnosis in FUS:...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f61d1328-913f-5443-9f1a-bd6478d6f8fb
DOI
10.1101/2024.05.14.594150
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
EZH2-driven immune evasion at disease presentation defines a targetable high-risk subset of acute leukemia exemplified by t(16;21) FUS::ERG AMLDOI 10.1101/2024.05.14.594150
Select a neighboring publication to make it the new centre.